- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05123248
Integrating the Use of Calibration-Free Continuous Monitoring for Pregnancy Glucose Profiling: I-Profile Study (I-Profile)
This study aims to test the following hypotheses in a longitudinal, observational study in pregnant women who will be randomized to received either a Blinded or Unblinded CGM sensor and followed-up 6-12 weeks after delivery:
- CF-CGM device is well tolerable and accurate for glucose level monitoring in women with a normal pregnancy.
- CF-CGM device is well tolerable and acceptable in women with GDM who are required intensive glucose monitoring on a daily basis during pregnancy and even after delivery.
- There are trimester-specific glucose profiles observed in the whole pregnancy.
- Pregnancies complicated with GDM would show a specific glucose profile that is different from non-GDM pregnancies (e.g. greater daily fluctuations, more episodes and longer duration of glucose spikes after meal).
- There is a good correlation between one-day glucose profile and OGTT test at 24-31 weeks gestation GDM screening.
- Pre-GDM screening glucose profiles is predictive of GDM diagnosis at 24-31 weeks gestation.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
GDM affects 5-10% of pregnant women in Europe, while the prevalence in Asian populations is significantly higher at approximately 15-20%. However, the GDM screening approaches, timing and targeted population still varies greatly in clinical practice all over the world, which makes the prevalence of GDM difficult to compare universally. Since the early days of the 21st century, the continuous glucose monitoring system (CGM) has been used for constant evaluation of glucose levels by measuring interstitial glucose concentrations. It can potentially improve diabetes care if used carefully with proper understanding of the characteristics of this system.
This is longitudinal, observational and hospital-based study. A total of 500 pregnant women will be recruited with consent form completion after meeting our inclusion criteria. The recruited women will then be randomly assigned to a Blinded and Unblinded CGM device.
All pregnant women aged 21 and above who plan to be followed up throughout pregnancy and intend to deliver at KKH and currently attending KKH for antenatal consultation during their early trimester will be approached by study research personnel, and will be followed up from then onwards. If they agree to take part in the study, consent will be signed at the first trimester clinic visit.
All recruited subjects will be randomized to put on a Blinded or Unblinded CGM device for 14 days from the first trimester (9-13 weeks), 18-23 weeks, 24-31 weeks, and 32-33 weeks. If a pregnant subject is diagnosed with GDM using International association of diabetes and pregnancy study groups (IADPSG) guidelines at KKH at 24-31 weeks gestation, she will be required to wear the sensor continuously until 38 weeks gestation, and will be followed up for another 14 days at the 6-12 weeks postnatal period.
Data will be collected through questionnaires and clinical measurements. The questionnaires include socio-economic factors, medical histories, lifestyle factors, health status, and home environment. Bio-physical measurements will be obtained from anthropometric measurements of participants, human biological materials such as blood, are collected from the participants at their follow-up time points with the I-PROFILE study upon their consent.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Kok Hian Tan, MD
- Telefoonnummer: +653941099
- E-mail: tan.kok.hian@singhealth.com.sg
Studie Contact Back-up
- Naam: Phaik Ling Quah, PhD
- Telefoonnummer: +6597732543
- E-mail: quah.phaik.ling@kkh.com.sg
Studie Locaties
-
-
-
Singapore, Singapore, 229899
- Werving
- KK Women's and Children's Hospital
-
Contact:
- Phaik Ling Quah, PhD
- Telefoonnummer: +6597732543
- E-mail: quah.phaik.ling@kkh.com.sg
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participants who are Singapore citizens or Singapore Permanent Residents, and plan to be followed up throughout pregnancy and intend to deliver at KKH;
- Aged 21 and above;
- Singleton pregnancy
Exclusion Criteria:
- Have serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days;
- Patients who have any other chronic disease such as chronic kidney disease.
- Unable to read or speak English
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Blinded Group
Participants in the blinded group will be wearing the sensor for 14 days without a reader.
After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
|
Participants in the blinded group will be wearing the sensor for 14 days without a reader.
Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.
After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
|
Experimenteel: Unblinded Group
Participants in the non-blinded group are required to wear the sensor for 14 days with an open reader.
The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
|
Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader.
Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.
The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Gestational Diabetes Mellitus (GDM)
Tijdsspanne: 24-31 weeks gestation
|
Clinical outcomes of Gestational Diabetes Mellitus (GDM) development determined by oral glucose tolerance test
|
24-31 weeks gestation
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
CGM summary metrics derived from extracted CGM glucose data
Tijdsspanne: First trimester: 9-13 weeks, Second trimester: 18-23 weeks, 24-31 weeks, 32-33 weeks
|
Glucose profiles extracted from the continous glucose monitoring (CGM) device
|
First trimester: 9-13 weeks, Second trimester: 18-23 weeks, 24-31 weeks, 32-33 weeks
|
Plasma glucose measures from OGTT
Tijdsspanne: 24-31 weeks gestation
|
Fasting, one hour and 2 hour glucose values obtained from OGTT
|
24-31 weeks gestation
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Applicability, acceptability, compliance of the blinded the CGM device use in a normal pregnancy.
Tijdsspanne: At 32-33 weeks gestation
|
Using a 10-item patient feedback survey
|
At 32-33 weeks gestation
|
Applicability, acceptability, compliance of the unblinded the CGM device use in a normal pregnancy.
Tijdsspanne: At 32-33 weeks gestation
|
Using a 14-item patient feedback survey
|
At 32-33 weeks gestation
|
Applicability, acceptability, compliance of the blinded CGM device use in a GDM pregnancy
Tijdsspanne: 6-12 weeks postnatal
|
Using 10-item patient feedback survey
|
6-12 weeks postnatal
|
Applicability, acceptability, compliance of the unblinded CGM device use in a GDM pregnancy
Tijdsspanne: 6-12 weeks postnatal
|
Using a 14-item patient feedback survey
|
6-12 weeks postnatal
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2018/2128
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Blinded Group
-
Chinese University of Hong KongActief, niet wervendIntellectuele handicap, MildHongkong
-
Karadeniz Technical UniversityVoltooidHemodialyse | Eenzaamheid | Geluk | Aanpassing | Dierondersteunde therapie | SymptoomKalkoen
-
National Jewish HealthNational Institute on Drug Abuse (NIDA)Actief, niet wervendHypnotische afhankelijkheid bij mensen met slapeloosheidVerenigde Staten
-
University of MichiganVoltooid
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalVoltooid
-
University of TennesseeNational Cancer Institute (NCI); Regional One HealthWervingGewichtsverlies | Overgewicht en obesitas | Gedrag, gezondheidVerenigde Staten
-
Loma Linda UniversityBaxter Healthcare CorporationVoltooidBloeding | Aangeboren hartfout | Chirurgie-geïnduceerde weefselverklevingenVerenigde Staten
-
Radboud University Medical CenterThe health Care Insurance Board (CVZ); Department of Preventive and Restorative...VoltooidTand, geïmpacteerdNederland
-
The Policy & Research GroupMathematica Policy Research, Inc.; The Office of Adolescent Health, HHSVoltooid
-
Cukurova UniversityVoltooidZwangerschap, hoog risico | Angst staat | SlaapkwaliteitKalkoen